Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Aptose Biosciences ( (TSE:APS) ).
Aptose Biosciences is advancing tuspetinib (TUS), a promising oral kinase inhibitor, as a frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. The TUS+VEN+AZA combination therapy shows potential in overcoming VEN resistance, offering broad efficacy and favorable safety in AML patients, including those with challenging genetic mutations. The ongoing clinical trials aim to establish a new standard of care for AML, targeting significant unmet needs in the market.
See more data about APS stock on TipRanks’ Stock Analysis page.